The device can detect potential warning signs of serious conditions.
Reese Pharmaceutical is launching a new at home colon cancer screening test as part of its diagnostic portfolio. The over-the-counter test is FDA approved and is available now.
According to a press release,1 the test is a fecal immunochemical test and is able to detect blood in the stool, even if it is not visible to the naked eye. This can be used as an early warning sign of colon cancer, along with other conditions like diverticulitis and polyps. The test has a suggested retail price of $19.99.
In a press release, Reese Pharmaceutical’s president Jeffrey Reese said, “90% of colon cancer-related deaths are thought to be preventable if caught early, and yet more than 29 million Americans are not screening for it. With colon cancer rates on the rise, it is more important than ever for people to be proactive. We're proud to introduce ColoTest to help meet this challenge by delivering a convenient, affordable, non-invasive screening option that enables people to identify invisible blood in stool, a key warning sign for colorectal cancer, diverticulitis, gastrointestinal disorders, colitis and polyps. This test is performed in the comfort of your own home with results at home as soon as 1 minute.”
Reese Pharmaceuticals details how the test works in its press release. Its designed to be easy to use and not require the help of another person. Essentially, the user just needs to collect a sample in the provided tube and add the sampler liquid. It should take less than a minute for results to appear.
While the test can be used to detect the presence of blood in the stool, it cannot provide a definitive diagnosis of any conditions. It’s simply meant to act as an early warning sign, and anyone who receives a positive test result should contact a doctor.
According to Reese Pharmaceuticals, the test was designed in response to the current state of cancer screenings. Typically, colonoscopies are used to screen for these conditions, but a large portion of the population does not regularly get these tests done. This is due to a variety of reasons, such as the test being uncomfortable and a lack of health insurance coverage. While the at-home test cannot replace a colonoscopy, it can at least provide users with an early warning that it might be time to get a more comprehensive test.
The test can be used by people of all ages. Typically, younger adults don’t get screened for colon cancer or other similar conditions, which can cause them to miss the early warning signs.
Reese Pharmaceutical Launches New At-Home Colon Cancer Screening Test. Reese Pharmaceutical. February 27, 2024. https://www.prnewswire.com/news-releases/reese-pharmaceutical-launches-new-at-home-colon-cancer-screening-test-302070648.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.